The large e‐Ultimaster is an all‐comer, single‐arm, prospective, and multicenter registry. The study was conducted worldwide across Europe, Asia, South America, and Africa to further evaluate the safety and performance of the Ultimaster DES system (Terumo Corporation, Tokyo, Japan) in an all‐comer clinical setting.9 Inclusion and exclusion criteria were described previously.9 Briefly, patients with coronary artery disease (reference vessel diameters between 2.5 and 3.5 mm) eligible for PCI using DES according to local hospital practice and who were treated using the Ultimaster stent were enrolled in the registry. Local institutional review board approval was obtained at each institution while subjects included in the registry were waived to provide informed consent.
Ultimaster des system
Manufactured by Terumo
Sourced in Japan
The Ultimaster DES system is a medical device designed for the treatment of coronary artery disease. It is a drug-eluting stent (DES) system that provides a minimally invasive solution for opening and supporting blocked arteries. The Ultimaster DES system is intended to be used by qualified healthcare professionals in appropriate clinical settings.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using ultimaster des system
1
Ultimaster DES System Evaluation
2
Ultimaster DES Registry: Outcomes in PAD
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The large e-ULTIMASTER is an all-comer, single-arm, prospective, and multicenter registry. The study was conducted worldwide across Europe, Asia, South-America, Middle-East and Africa to further evaluate the safety and performance of the Ultimaster DES system (Terumo Corporation, Tokyo, Japan) in an all-comer clinical setting. Inclusion and exclusion criteria were described previously [13] (link). Briefly, patients with CAD, with reference vessel diameters between 2.5 and 3.5 mm, eligible for PCI according to local hospital practice, and who were treated using the Ultimaster stent, were enrolled in the registry. Local institutional review board approval was obtained at each institution and all patients provided written informed consent.
The present study analyzed the clinical outcomes of patients who have known PAD. Patients were grouped into (1) those with known PAD; or (2) those without known PAD. Each site applied their routine definition of PAD; there was no per-protocol definition.
The present study analyzed the clinical outcomes of patients who have known PAD. Patients were grouped into (1) those with known PAD; or (2) those without known PAD. Each site applied their routine definition of PAD; there was no per-protocol definition.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!